Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 11/19/15  and contains information from public web pages and contributions from the ZoomInfo community.

Mr. Michael L. Kranda

Wrong Michael L. Kranda?

Chief Executive Officer

Phone: (425) ***-****  
Email: m***@***.com
Local Address:  Washington , United States
Company Description: BEAT BioTherapeutics Corp. (BEATBio) is developing BB-R12, a novel biological therapy with the potential to revolutionize the treatment of heart failure. Heart...   more

Employment History

Board Memberships and Affiliations


  • MBA
  • BA , finance
    University of Washington
156 Total References
Web References
Team | BEAT BioTherapeutics, 19 Nov 2015 [cached]
Michael Laflamme, M.D., Ph.D. - Scientific co-founder and Scientific Advisory Board member. Associate Professor of Pathology, University of Washington Center for Cardiovascular Biology. Dr. Laflamme is a leader in the field of cardiac physiology, stem cell-derived cardiac tissues and cardiac pacemaker cells.
Team | BEAT BioTherapeutics, 19 Nov 2015 [cached]
Michael Kranda, MBA - Chief Executive Officer, President and Director - Mr. Kranda has over 25 years of biotech operating, finance and corporate development experience. Most recently Mr. Kranda was CEO of Vaccinogen, a cancer vaccine company. Mr. Kranda served as Managing Director of Vulcan Capital for several years, where he led all aspects of their Life Sciences investment efforts. Mr. Kranda was also the CEO of Oxford GlycoSciences, a pioneer in proteomic based drug and diagnostic product development.
Mr. Kranda started his biotech career at Immunex Corporation where he served as President, COO and Director and is currently a Director for PTC Therapeutics, Inc. (NASDAQ: PTCT).
Michael Kranda - Chief Executive Officer and President.
::: Raven Announces ... [cached]
::: Raven Announces Appointment of Michael Kranda as Chairman of the BoardRaven Announces Appointment of Michael Kranda as Chairman of the Board
Raven Announces Appointment of Michael Kranda as Chairman of the Board
Raven biotechnologies (UNITED STATES)
November 30, 2007
SOUTH SAN FRANCISCO, Calif., Nov. 30 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the development of monoclonal antibody therapeutics (MAbs) for treating cancer, today announced the appointment of Michael Kranda as chairman of the board.Mr. Kranda replaces Bill Young who remains on the Raven board as a director.
Mr. Kranda led life sciences venture investments as Managing Director for Vulcan Capital through 2006 and continues to consult for Vulcan.He sits on the board of directors of several companies including BiPar Sciences and PTC Therapeutics.Mr. Kranda was the chief executive officer of Oxford GlycoSciences (OGS) for six years, establishing the company as the leading proteomics platform-based drug discovery company.
Prior to that, Mr. Kranda spent 12 years at Immunex (now Amgen) where he served as president and chief operating officer and director.
Anesiva Names Michael L. ..., 1 Feb 2012 [cached]
Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors Anesiva Names Michael L. Kranda as President, Chief Executiv | Press Release Press Related Press Releases
Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors
Inc. (Nasdaq: ANSV) today announced the appointment of Michael L. Kranda as president, chief executive officer and a member of the company's board of directors, effective June 16, 2008. Mr. Kranda succeeds John P. McLaughlin,
"Michael is the ideal person to lead Anesiva as it transitions from a drug
Mr. Kranda is a seasoned biopharmaceutical executive who brings two decades of commercial operating and corporate development experience to Anesiva. Most recently, he was Managing Director for biotechnology and life science investments at Vulcan, Inc. where he played an active role in the product, business development and financing activities of multiple portfolio companies.
said Mr. Kranda. "I look forward to working with the talented employees of Anesiva to achieve these goals and build long-term value for stockholders."
"The members of the Anesiva board welcome Michael and thank John for his
Vaccinogen Names Veteran Biotech Executive Michael Kranda President & CEO
PTC Therapeutics: Board of Directors, 30 April 2015 [cached]
Michael Kranda
Michael Kranda has served as a member of PTC's board of directors since December 2003. Since September 2006, Mr. Kranda has served as a consultant to Vulcan Capital, the private investment group of Vulcan Inc., and Mr. Kranda served as Managing Director of biotechnology venture investments at Vulcan Capital from September 2003 to September 2006. From July 1996 to July 2002, Mr. Kranda served as Chief Executive Officer at Oxford GlycoSciences, a biotechnology company. Prior to joining Oxford GlycoSciences, Mr. Kranda was President and Chief Operating Officer at Immunex Corporation (now Amgen), a biopharmaceutical company.
Mr. Kranda currently serves as Chief Executive Officer and a director of BEAT BioTherapeutics Corporation, a gene therapy company. Mr. Kranda received a B.A. and an M.B.A from the University of Washington School of Business.
Other People with the name "Kranda":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.